XHKG
2327
Market cap111mUSD
Oct 09, Last price
0.21HKD
1D
-3.70%
1Q
-16.80%
Jan 2017
-45.26%
IPO
-51.69%
Name
Meilleure Health International Industry Group Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Meilleure Health International Industry Group Limited functions as an investment holding company, overseeing a broad spectrum of ventures in Hong Kong, the People's Republic of China, and other international markets. Its diverse operations include industrial hemp, healthcare-related services, trading, various agency services, and both property investment/leasing and development. The company actively engages in the commerce of construction supplies, the creation and sale of residential real estate, property asset management, and the distribution of health-related goods. Furthermore, it provides real estate brokerage, services focused on the application of cannabidiol (CBD) derivatives, and comprehensive health management offerings, such as anti-aging treatments, aesthetic medicine, and general wellness consulting. It also acts as an agent for healthcare product sales. Formerly known as U-Home Group Holdings Limited, the company rebranded to Meilleure Health International Industry Group Limited in March 2017. Its primary corporate office is located in Admiralty, Hong Kong.
Key people
Wentao Zeng
Executive Co-Chairman of the Board · since 2019
Xuzhou Zhou
Executive Co-Chairman of the Board · since 2019
Wen Chuan Zhou
Chief Executive Officer, Executive Director · since 2025
Chief Financial Officer, Company Secretary · since 2019
Non-Executive Director · since 2015
Chi Wai Chau
Independent Non-Executive Director · since 2013
Non-Executive Independent Director · since 2024
Peng Wu
Non-Executive Independent Director · since 2019
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||